Search clinical trials for: SHP611

Total 52 results

Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (EMBOLDEN)

Metachromatic Leukodystrophy (MLD)

United States, Canada, Belgium, Israel, Netherlands, United Kingdom, Germany, Spain, Japan, Brazil, Argentina, France, Greece, Italy
Shire

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

Healthy Volunteers

United States
Shire

Completed

Long-Term Safety Of PF-00547659 In Ulcerative Colitis (TURANDOT II)

Ulcerative Colitis

Korea, Republic of, United States, Spain, Australia, Canada, Israel, Serbia, Netherlands, Belgium, Italy, New Zealand, Austria, Bulgaria, Czechia, France, Germany, Hungary, Poland, Russian Federation, Slovakia, South Africa
Shire

Terminated

A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Fabry Disease

Spain, Greece, Germany, Portugal, Canada, Finland, Poland, Sweden
Takeda

Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (CARMEN CD 307)

Crohn's Disease

Spain, United States, Korea, Republic of, Australia, Romania, Hungary, Israel, Italy, Croatia, Belgium, Bulgaria, Germany, Poland, Portugal, Argentina, United Kingdom, Greece, New Zealand, Austria, Bosnia and Herzegovina, Colombia, Eston... and more
Shire

Completed

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Healthy Volunteers

United States
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (CARMEN CD 305)

Crohn's Disease

United States, Australia, Romania, Israel, Italy, Croatia, South Africa, Germany, Poland, United Kingdom, Austria, Japan, Lithuania, Netherlands, Russian Federation, Serbia
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (CARMEN CD 306)

Crohn's Disease

Spain, United States, Korea, Republic of, Hungary, Turkey, Belgium, Bulgaria, Argentina, Greece, New Zealand, Bosnia and Herzegovina, Colombia, Estonia, Ireland, Japan, Lebanon, Mexico, Portugal, Slovakia, Ukraine
Shire

Completed

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children (SPRING)

Hereditary Angioedema

United States, Canada, Germany, Hungary, Spain
Mirum Pharmaceuticals, Inc.

Terminated

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States, United Kingdom, Canada, Puerto Rico
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (RAISE)

Sickle Cell Disease

United States
Shire

Completed

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

Healthy Volunteers

United States
Shire
Takeda Development Center Americas, Inc.

Withdrawn

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

COVID-19 Pneumonia
Baxalta now part of Shire

Terminated

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Hemophilia B

Turkey, Spain
Shire
Takeda Development Center Americas, Inc.

Completed

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (SOAR-HI)

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

United States, Spain, Canada, United Kingdom, France, Germany, Italy
Mirum Pharmaceuticals, Inc.

Withdrawn

A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Healthpoint

Withdrawn

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

Pressure Ulcers
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Mirum Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

Non-Alcoholic Steatohepatitis

United States
Shire
Takeda Development Center Americas, Inc.

Completed

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

Nervous System Diseases

Japan
Shire

Completed

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Shire

Terminated

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)

Ulcerative Colitis

United States, Australia, Russian Federation, Romania, Brazil, Israel, Germany, Italy, Croatia, Netherlands, Poland, United Kingdom, Austria, Japan, Lithuania, Serbia, South Africa, Czechia
Shire

Terminated

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Hungary, Portugal, Turkey, Belgium, Bulgaria, New Zealand, Argentina, Greece, Bosnia and Herzegovina, Colombia, Estonia, Japan, Mexico, Slovakia, Ukraine, Ireland, Canada, Switzer...
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Shire

Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

Primary Sclerosing Cholangitis

United States, United Kingdom, Israel, Germany, Canada
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Shire

Completed

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Ocular Hypertension | Primary Open-angle Glaucoma (POAG)

United States
Shanghai Zhongshan Hospital
The First Affiliated Hospital of Anhui Medical University; Beijing Ditan Hospital and other collaborators

Unknown

Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices (PUoA-EIoTA)

Cirrhosis | Gastric Varices

China
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Mirum Pharmaceuticals, Inc.

Completed

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK)

Biliary Atresia

United States, United Kingdom, China, Taiwan, Germany, Poland, Singapore, Vietnam
Mirum Pharmaceuticals, Inc.

Terminated

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) (OHANA)

Intrahepatic Cholestasis of Pregnancy

United States, United Kingdom, New Zealand
Mirum Pharmaceuticals, Inc.

Completed

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

Non-Alcoholic Steatohepatitis

United States
Takeda

Completed

A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Cytomegalovirus (CMV)

Japan
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

Primary Biliary Cholangitis | PBC

United States, United Kingdom, Israel, Germany, Italy, France
Mirum Pharmaceuticals, Inc.

Completed

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Healthy Volunteers

United States
Shire

Terminated

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

Healthy Volunteers

United States
Healthpoint

Terminated

Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury

Spinal Cord Injury | Pressure Ulcers

United States
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Shire

Terminated

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

Adenoviral Conjunctivitis

United States, Puerto Rico
Shire

Completed

Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo

Bacterial Conjunctivitis

United States, Australia, Austria, Israel, Poland, Hungary, South Africa, Canada, Estonia, France, Italy, Spain, Puerto Rico
Shire

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

Healthy Volunteers

United States
Shire
Takeda Development Center Americas, Inc.

No longer available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Angioedema | Hereditary Angioedema (HAE)

United States, Canada, Germany, Hungary, Spain
Shire

Terminated

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo

Adenoviral Conjunctivitis

United States, Israel, France, India, Australia, Austria, Spain, Estonia, Hungary, Poland, South Africa, Canada, Germany, Italy, Peru, United Kingdom
Shire

Completed

Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan

Nervous System Diseases

Japan
Takeda

Recruiting

A Survey of Midazolam in People With Status Epilepticus

Epilepsy

Japan

Search clinical trials for: SHP611

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations